Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
ACURA PHARMS INC (ACUR)
Last acura pharms inc earnings: 8/14 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.acurapharm.com/investor-relations
Company Research
Source: GlobeNewswire
PALATINE, Ill., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx™ excess oral abuse deterrent drug LTX-03 identified a formulation that we believe optimizes the balance between providing therapeutic blood levels of drug for pain relief at a single tablet dose while retarding the bioavailability of drug when higher buffer levels are ingested. The Company intends to submit an Investigational New Drug application (IND) for LTX-03 to the US Food and Drug Administration (FDA) in the first quarter of 2018 and advance to clinical development for a New Drug Application (NDA). Current FDA approved abuse deterrent opioid formulations do not address abuse by swallowing excess numbers of tablets. The patented LIMITx technology works by neutralizing stomach acid with buffering ingredients as increasing
Show less
Read more
Impact Snapshot
Event Time:
ACUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACUR alerts
High impacting ACURA PHARMS INC news events
Weekly update
A roundup of the hottest topics
ACUR
Sec Filings
- 3/26/24 - Form 8-K
- 3/18/24 - Form 8-K
- ACUR's page on the SEC website